Payment overview · 2025
General Payments
$1,975.34
86 reported records · 24 companies
Healthcare provider profile · identity verified
Fausto A Gonzalez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTH OZONE PARK, NY · NPI 1124087713
Verified facts
What the public records show
CMS Open Payments records show Fausto A Gonzalez, MD received $1,975.34 in general payments during 2025 across 86 reported records.
Novo Nordisk Inc accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Ibsrela, Jardiance, Kerendia, Linzess, Mounjaro, Nurtec Odt, Ozempic, Relistor, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar, Xifaxan, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 698 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
Ardelyx, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBSRELA as an associated drug or biological on 59980 records involving 18215 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ibsrela by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 537 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 504 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 504 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 791 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Nurtec Odt by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Relistor by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $355.98 | 18.0% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $216.67 | 11.0% | 9 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $210.74 | 10.7% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $159.04 | 8.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $119.10 | 6.0% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $102.25 | 5.2% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.13 | 5.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.33 | 4.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.44 | 4.0% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $68.92 | 3.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.33 | 2.8% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.59 | 2.5% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $48.70 | 2.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.67 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.85 | 2.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.44 | 2.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.37 | 1.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.63 | 1.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.63 | 1.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.35 | 1.2% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $20.99 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.72 | 0.9% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.85 | 0.9% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $16.62 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,975.34 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $336.48 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $216.67 | 9 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $168.50 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $135.24 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $105.02 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $102.25 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $102.13 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $92.14 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $89.91 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $81.33 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $74.05 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $63.66 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $49.59 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $48.70 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $48.67 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.24 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.54 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.44 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $38.90 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $37.37 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.63 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.48 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 74 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 301 | exact normalized | Medicare Part D |
| IBSRELA ibsrela |
2025 | Ibsrela | 2024 | 23 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 504 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 77 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 698 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 131 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 791 | exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 64 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 112 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 141 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
698 | 95 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
141 | 26 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| Ardelyx, Inc. Exact reporting entity; no affiliate inference |
2025 | IBSRELA open payments reported associated product |
CMS Open Payments — General Payments 59980 supporting records · 18215 recipient NPIs · example record 1247828901 |
Ibsrela · 2024 Exact normalized brand match · 1 Part D row |
23 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
537 | 94 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
136 | 37 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
77 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
504 | 78 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
112 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
504 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
103 | 14 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
791 | 104 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
301 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
131 | 29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
186 | 32 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2015 | 340 |
| Diclofenac Sodium | Diclofenac Sodium | 2002 | 368 |
| Omeprazole | Omeprazole | 1874 | 293 |
| Metformin Hcl | Metformin Hcl | 1768 | 266 |
| Amlodipine Besylate | Amlodipine Besylate | 1444 | 237 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1128 | 174 |
| Meloxicam | Meloxicam | 962 | 185 |
| Meclizine Hcl | Meclizine Hcl | 883 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 881 | 131 |
| Gabapentin | Gabapentin | 878 | 153 |
| Lisinopril | Lisinopril | 862 | 138 |
| Simvastatin | Simvastatin | 833 | 137 |
| Hydrochlorothiazide | Hydrochlorothiazide | 824 | 139 |
| Ibuprofen | Ibuprofen | 803 | 129 |
| Ozempic | Semaglutide | 791 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 768 | 131 |
| Montelukast Sodium | Montelukast Sodium | 741 | 122 |
| Linzess | Linaclotide | 698 | 95 |
| Fluticasone Propionate | Fluticasone Propionate | 692 | 146 |
| Losartan Potassium | Losartan Potassium | 651 | 121 |
| Famotidine | Famotidine | 644 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 625 | 114 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 597 | 126 |
| Clopidogrel | Clopidogrel Bisulfate | 548 | 85 |
| Nifedipine Er | Nifedipine | 541 | 94 |
| Farxiga | Dapagliflozin Propanediol | 537 | 94 |
| Ammonium Lactate | Ammonium Lactate | 534 | 90 |
| Lidocaine | Lidocaine | 530 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 519 | 95 |
| Jardiance | Empagliflozin | 504 | 78 |
| Quetiapine Fumarate | Quetiapine Fumarate | 501 | 80 |
| Alendronate Sodium | Alendronate Sodium | 450 | 63 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 441 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 433 | 79 |
| Restasis | Cyclosporine | 406 | 54 |
| Vascepa | Icosapent Ethyl | 397 | 61 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 395 | 101 |
| Donepezil Hcl | Donepezil Hcl | 388 | 64 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 387 | 52 |
| Furosemide | Furosemide | 378 | 58 |
| Clobetasol Propionate | Clobetasol Propionate | 370 | 67 |
| Diclofenac Potassium | Diclofenac Potassium | 367 | 87 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 366 | 68 |
| Naproxen | Naproxen | 361 | 67 |
| Celecoxib | Celecoxib | 349 | 70 |
| Diclofenac Epolamine | Diclofenac Epolamine | 349 | 85 |
| Zolpidem Tartrate | Zolpidem Tartrate | 340 | 75 |
| Januvia | Sitagliptin Phosphate | 339 | 45 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 316 | 50 |
| Glipizide Er | Glipizide | 314 | 56 |
| Meloxicam | Meloxicam, Submicronized | 314 | 85 |
| Oxycodone Hcl | Oxycodone Hcl | 310 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 307 | 41 |
| Hydrocortisone | Hydrocortisone | 303 | 62 |
| Eliquis | Apixaban | 301 | 44 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 295 | 44 |
| Megestrol Acetate | Megestrol Acetate | 276 | 60 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 256 | 46 |
| Carvedilol | Carvedilol | 255 | 47 |
| Pioglitazone Hcl | Pioglitazone Hcl | 251 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 233 | 61 |
| Atenolol | Atenolol | 227 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 222 | 43 |
| Ketoconazole | Ketoconazole | 218 | 40 |
| Enalapril Maleate | Enalapril Maleate | 209 | 28 |
| Azithromycin | Azithromycin | 204 | 147 |
| Sucralfate | Sucralfate | 197 | 42 |
| Glimepiride | Glimepiride | 195 | 31 |
| Xiidra | Lifitegrast | 195 | 23 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 193 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 186 | 39 |
| Trulance | Plecanatide | 186 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 184 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 182 | 31 |
| Mupirocin | Mupirocin | 180 | 48 |
| Glipizide | Glipizide | 173 | 30 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 163 | 38 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 161 | 30 |
| Buspirone Hcl | Buspirone Hcl | 156 | 31 |
| Sertraline Hcl | Sertraline Hcl | 149 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 148 | 27 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 144 | 43 |
| Procto-Med Hc | Hydrocortisone | 144 | 27 |
| Valacyclovir | Valacyclovir Hcl | 142 | 29 |
| Vraylar | Cariprazine Hcl | 141 | 26 |
| Dutasteride | Dutasteride | 139 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 136 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 135 | 23 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 134 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 134 | 20 |
| Prednisone | Prednisone | 133 | 60 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 133 | 30 |
| Nurtec Odt | Rimegepant Sulfate | 131 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 127 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 124 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 122 | 17 |
| Trintellix | Vortioxetine Hydrobromide | 122 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 18 |
| Tramadol Hcl | Tramadol Hcl | 119 | 26 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 112 | 27 |
| Entresto | Sacubitril/Valsartan | 112 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 13 |
| Memantine Hcl | Memantine Hcl | 111 | 20 |
| Alprazolam | Alprazolam | 109 | 29 |
| Lubiprostone | Lubiprostone | 108 | 16 |
| Finasteride | Finasteride | 107 | 25 |
| Cromolyn Sodium | Cromolyn Sodium | 105 | 23 |
| Allopurinol | Allopurinol | 104 | 19 |
| Trulicity | Dulaglutide | 103 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 99 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 96 | 27 |
| Sumatriptan | Sumatriptan | 93 | 13 |
| Latanoprost | Latanoprost | 92 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 33 |
| Breo Ellipta | Fluticasone/Vilanterol | 88 | 18 |
| Fluocinonide | Fluocinonide | 88 | 19 |
| Pregabalin | Pregabalin | 88 | 18 |
| Diclofenac Sodium Er | Diclofenac Sodium | 87 | 19 |
| Mirtazapine | Mirtazapine | 87 | 17 |
| Doxepin Hcl | Doxepin Hcl | 84 | 30 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 84 | 18 |
| Xarelto | Rivaroxaban | 84 | 13 |
| Valsartan | Valsartan | 83 | 13 |
| Mounjaro | Tirzepatide | 82 | 14 |
| Nitroglycerin | Nitroglycerin | 82 | 11 |
| Calcipotriene | Calcipotriene | 80 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 78 | 14 |
| Chlorthalidone | Chlorthalidone | 77 | 12 |
| Kerendia | Finerenone | 77 | 25 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 75 | 16 |
| Creon | Lipase/Protease/Amylase | 74 | 13 |
| Amantadine | Amantadine Hcl | 73 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 57 |
| Clonidine Hcl | Clonidine Hcl | 71 | 12 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 70 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 69 | 11 |
| Mesalamine | Mesalamine | 69 | 15 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 68 | 21 |
| Clotrimazole | Clotrimazole | 68 | 13 |
| Acyclovir | Acyclovir | 67 | 13 |
| Ibu | Ibuprofen | 67 | 16 |
| Novolog Flexpen | Insulin Aspart | 67 | 15 |
| Colchicine | Colchicine | 65 | 14 |
| Proctozone-Hc | Hydrocortisone | 65 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 48 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 13 |
| Labetalol Hcl | Labetalol Hcl | 64 | 12 |
| Rexulti | Brexpiprazole | 64 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 63 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 63 | 13 |
| Ketoprofen | Ketoprofen | 62 | 16 |
| Amoxicillin | Amoxicillin | 61 | 43 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 61 | 12 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 61 | 33 |
| Ezetimibe | Ezetimibe | 61 | 13 |
| Single Use Swab | Alcohol Antiseptic Pads | 60 | 28 |
| Lansoprazole | Lansoprazole | 59 | 12 |
| Metformin Hcl Er | Metformin Hcl | 59 | 13 |
| Levetiracetam | Levetiracetam | 58 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 53 | 17 |
| Fenofibrate | Fenofibrate | 53 | suppressed |
| Lactulose | Lactulose | 53 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 53 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 52 | suppressed |
| Methocarbamol | Methocarbamol | 52 | 22 |
| Mometasone Furoate | Mometasone Furoate | 51 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 50 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 49 | 13 |
| Prolensa | Bromfenac Sodium | 49 | suppressed |
| Glipizide Xl | Glipizide | 48 | 11 |
| Zenpep | Lipase/Protease/Amylase | 48 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 46 | 19 |
| Baclofen | Baclofen | 46 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 46 | suppressed |
| Clonazepam | Clonazepam | 46 | 17 |
| Spironolactone | Spironolactone | 46 | suppressed |
| Ciclopirox | Ciclopirox | 45 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 43 | suppressed |
| Rybelsus | Semaglutide | 43 | suppressed |
| Dexilant | Dexlansoprazole | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 39 | 23 |
| Chlorzoxazone | Chlorzoxazone | 38 | 13 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Loperamide | Loperamide Hcl | 35 | 11 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 29 |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Repaglinide | Repaglinide | 33 | suppressed |
| Rivastigmine | Rivastigmine | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | 17 |
| Jublia | Efinaconazole | 31 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 31 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 30 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 30 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 29 | 12 |
| Nystatin | Nystatin | 29 | 12 |
| Brilinta | Ticagrelor | 28 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Leflunomide | Leflunomide | 28 | suppressed |
| Xifaxan | Rifaximin | 28 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 27 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 12 |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Nexium | Esomeprazole Magnesium | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Lumigan | Bimatoprost | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Ibsrela | Tenapanor Hcl | 23 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Relistor | Methylnaltrexone Bromide | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 21 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 20 | suppressed |
| Letrozole | Letrozole | 20 | suppressed |
| Tretinoin | Tretinoin | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Acarbose | Acarbose | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Oxycontin | Oxycodone Hcl | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Prolia | Denosumab | 19 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 19 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Naproxen Sodium Er | Naproxen Sodium | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 16 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 15 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Atovaquone | Atovaquone | 15 | suppressed |
| Budesonide Er | Budesonide | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Terconazole | Terconazole | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 12 |
| Ramipril | Ramipril | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alphagan P | Brimonidine Tartrate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Dymista | Azelastine/Fluticasone | 13 | suppressed |
| Erythromycin-Benzoyl Peroxide | Erythromycin/Benzoyl Peroxide | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nulojix | Belatacept | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,975.34 · 86 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, CREON, DUPIXENT, ELIQUIS, FANAPT, IBSRELA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NALOCET, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLATE, RECORLEV, RELISTOR, REPATHA, REXULTI, Rybelsus, Symbravo, TANLOR, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 31 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error